(Q38119843)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23832092%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

title

EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23832092%20AND%20SRC:MED&resulttype=core&format=json

lymphoproliferative disorders

4 March 2020

main subject

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23832092%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

author name string

L Rasche

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23832092%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

M Kapp

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23832092%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

H Einsele

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23832092%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

language of work or name

English

0 references

publication date

8 July 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23832092%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

4 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23832092%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

volume

49

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23832092%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23832092%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

page(s)

163-167

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23832092%20AND%20SRC:MED&resulttype=core&format=json

Examining the origin of posttransplant lymphoproliferative disorder in a patient after a second allogeneic hematopoeitic stem cell transplantation for relapsed BCR-ABL positive acute lymphoblastic leukemia.

4 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.96

Posttransplant lymphoproliferative disorder after umbilical cord blood transplantation in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.96

Allogeneic haematopoietic stem-cell transplantation with reduced intensity conditioning for advanced stage Hodgkin's lymphoma in Sweden: high incidence of post transplant lymphoproliferative disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.96

EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.96

Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.96

Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.96

Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.96

Epstein-Barr virus early-antigen antibodies before allogeneic haematopoietic stem cell transplantation as a marker of risk of post-transplant lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.96

Epstein-Barr virus infections after allogeneic stem cell transplantation: a comparison between non-malignant and malignant hematological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.96

Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.96

Prospective evaluation of epstein-barr virus reactivation after stem cell transplantation: association with monoclonal gammopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.96

Epstein-Barr virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.96

A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.96

Processing of two latent membrane protein 1 MHC class I epitopes requires tripeptidyl peptidase II involvement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.96

An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.96

Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.96

Preemptive Therapy of EBV-Related Lymphoproliferative Disease after Pediatric Haploidentical Stem Cell Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.96

CD20-negative Epstein-Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.96

Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.96

Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.96

Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.96

Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.96

Epstein-Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.96

Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.96

Rituximab administration within 6 months of T cell-depleted allogeneic SCT is associated with prolonged life-threatening cytopenias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.96

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.96

Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.96

A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.96

Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.96

Haploidentical hematopoietic transplantation: current status and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.96

Selectively T cell-depleted allografts from HLA-matched sibling donors followed by low-dose posttransplantation immunosuppression to improve transplantation outcome in patients with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.96

Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.96

Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years' experience in a single institute

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.96

Detection of Epstein-Barr virus DNA in plasma from patients with lymphoproliferative disease after allogeneic bone marrow or peripheral blood stem cell transplantation

21 January 2018

1 reference

12 December 2020

Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders

1 reference

12 December 2020

Assessment of cellular origin and EBV status in a PTLD after double cord blood transplantation

1 reference

12 December 2020

Prior immunosuppressive therapy with antithymocyte globulin increases the risk of EBV-related lymphoproliferative disorder following allo-SCT for acquired aplastic anaemia

1 reference

12 December 2020

Post-transplant lymphoproliferative disorder

1 reference

12 December 2020

Intravenously administered rituximab induces remission of EBV associated non Hodgkin lymphoma confined to the brain in a patient after allogeneic stem cell transplantation

1 reference

12 December 2020

Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.

1 reference

12 December 2020

The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.

1 reference

12 December 2020

Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation

1 reference

12 December 2020

Malignancies after hematopoietic stem cell transplantation: many questions, some answers

1 reference

12 December 2020

Identifiers

DOI

10.1038/BMT.2013.96

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23832092%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

4 March 2020

1027644592

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23832092%20AND%20SRC:MED&resulttype=core&format=json